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Katherine Oberwager, BA, RN
Mentor: Linda Samia, PhD, RN

Purpose

Evidence Synthesis

To answer the clinical PICOT question: in adults with
obsessive compulsive disorder (OCD), how does
augmenting a selective serotonin reuptake inhibitor
(SSRI) with N-acetyl-cysteine (NAC) compare to
monotherapy with an SSRI in terms of symptom severity
and to translate this evidence into practice.

• One RCT concluded NAC as a treatment adjunct to
SSRI was more successful than placebo with SSRI (p
< 0.001)¹
• Two systematic reviews concluded NAC is
efficacious in as a treatment adjunct with SSRI for
OCD based on three case reports and the
3,6
aforementioned RCT
• One systematic review postulated that OCD may be
heterogeneous in nature, which is why NAC may not
be successful for glutamate-independent OCD based
off of six retrospective case reports with various
outcomes3
• One RCT had non-significant results for overall YBOCS score (p = 0.39), but significant results for
compulsion subscale (p = 0.0013)5
• All studies conclude that NAC is a very inexpensive,
accessible medication, with low risk1,3,5,6,7

Background
•
•
•
•

•

•
•

OCD is a debilitating psychiatric diagnosis that
4
affects 1-2% of the population
The gold standard of treatment for OCD is selective1
serotonin-reuptake-inhibitor (SSRI)
Up to 40% of OCD patients do not receive a clinical
3
response from SSRIs
The exact etiology of OCD is unknown, but
literature has pointed to abnormalities in glutamate
metabolism7
The Yale-Brown Obsessive Compulsive Scale (YBOCS) is often used to assess severity of OCD
symptoms1
NAC has been explored as a potential glutamate
modulating therapy for OCD2
NAC is an over the counter medication that is
affordable, accessible and has a low side effect
2
profile

Evidence Appraisal
Databases: CINAHL, Cochrane, Central Register of
Controlled Trials, EBSCO, Medline, Nursing and Allied
Health Collection: Basic, PsychARTICLES, PsychINFO
Keywords: obsessive compulsive disorder, OCD, nacetyl-cysteine, NAC
Inclusion criteria: RTCs, systematic reviews,
& case reports published between 2010-2017
Exclusion criteria: articles not specific to OCD, articles
not specific to NAC
Final sample: Two double blind randomized placebo
controlled trials, three systematic reviews

Translation to Practice
• Given the low side-effect profile, low cost, and
accessibility, trialing OCD in treatment refractory
OCD is appropriate
• Trial NAC at 600mg BID for 1 month, and if
tolerated, titrate up to 2400-3000mg/ day for eight
weeks. If successful continue (YBOCS score <15 or
patient report) , if unsuccessful (YBOCS score >15,
patient report, discontinue

Proposed Evaluation
• Pilot trial in community mental health center using in
patients with OCD who have failed two first line
psychotropic agents
• Biweekly check ins with patient to interview and
administer Y-BOCS every visit for eight weeks
• Present results to practice at prescriber meeting

Conclusion
•
•

The results are promising for utilizing NAC in OCD,
but further research is needed with larger trials
Given the benign nature of NAC and potential
efficacy it is appropriate to use in treatment
refractory OCD, defined as at least two unsuccessful
trials for patients who were treated with two
different first line medications
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